Overview

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol
Phase:
Phase 2
Details
Lead Sponsor:
Ocuphire Pharma, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Phentolamine